Trials / Terminated
TerminatedNCT03969420
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of alvocidib in patients with AML who have either relapsed from or are refractory to venetoclax in combination with azacytidine or decitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alvocidib (flavopiridol) and cytarabine (Ara-C) | Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection |
| DRUG | Alvocidib (flavopiridol) | Administered intravenously |
Timeline
- Start date
- 2020-01-15
- Primary completion
- 2021-04-22
- Completion
- 2021-05-14
- First posted
- 2019-05-31
- Last updated
- 2023-11-09
- Results posted
- 2022-10-19
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03969420. Inclusion in this directory is not an endorsement.